Decision: Favourable
Study Title:
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
NREC Code:
21-NREC-CT-011
Decision:
Favourable
Meeting Date:
07/07/2021
Study Type:
CT application
Principal Investigator:
Dr Jarushka Naidoo
PI Institution:
Beaumont Hospital
Sponsor:
NOVARTIS Pharma AG delegated TRIO CRO